価格表

在庫・価格 : 2024年04月23日 16時09分 現在

商品名 商品コード メーカー 包装 価格 在庫 リスト
Anti-SARS-CoV-2 (COVID-19) nucleocapsid, Rabbit-Mono(HL344)
データシート
GTX635679 GNTジーンテックス
GeneTex International Corporation
25 μl ¥24,000
(未発注)
追加

在庫・価格 : 2024年04月23日 16時09分 現在

Anti-SARS-CoV-2 (COVID-19) nucleocapsid, Rabbit-Mono(HL344)

  • 商品コード:GTX635679
  • メーカー:GNT
  • 包装:25μl
  • 価格: ¥24,000
  • 在庫:無(未発注)
使用文献
No. 文献情報 備考 参照
1 Shapira T. et al., Shapira T., bioRxiv, 2021

PubMed
2 Ruetalo N et al. Antibody Response against SARS-CoV-2 and Seasonal Coronaviruses in Nonhospitalized COVID-19 Patients. mSphere 2021 02;6(1)
Ruetalo N et al
2021/01/01
PubMed
3 Song E et al. Neuroinvasion of SARS-CoV-2 in human and mouse brain. J Exp Med 2021 03;218(3)
Song E et al
2021/01/01
PubMed
4 Heaton BE et al. SRSF protein kinases 1 and 2 are essential host factors for human coronaviruses including SARS-CoV-2. bioRxiv 2020 Aug;
Heaton BE et al
2020/01/01
PubMed
5 Ramani A et al. SARS-CoV-2 targets neurons of 3D human brain organoids. EMBO J 2020 10;39(20):e106230
Ramani A et al
2020/01/01
PubMed
6 Eric Song et al., Eric Song, bioRxiv, 2020

PubMed
7 Song E et al. Neuroinvasion of SARS-CoV-2 in human and mouse brain. bioRxiv 2020 Sep;
Song E et al
2020/01/01
PubMed
8 Sasaki M et al. SARS-CoV-2 Bearing a Mutation at the S1/S2 Cleavage Site Exhibits Attenuated Virulence and Confers Protective Immunity. mBio 2021 08;12(4):e0141521
Sasaki M et al
2021/01/01
PubMed
9 Sacco MD et al. Structure and inhibition of the SARS-CoV-2 main protease reveals strategy for developing dual inhibitors against M<sup>pro</sup> and cathepsin L. bioRxiv 2020 Jul;
Sacco MD et al
2020/01/01
PubMed
10 . Pharmacological activation of STING blocks SARS-CoV-2 infection. Sci Immunol 2021 05;6(59)

2021/01/01
PubMed
11 Garc鱈a-Dorival I et al. Identification of Niemann-Pick C1 protein as a potential novel SARS-CoV-2 intracellular target. Antiviral Res 2021 10;194:105167
Garc鱈a-Dorival I et al
2021/01/01
PubMed
12 Asaka MN et al. Highly susceptible SARS-CoV-2 model in CAG promoter-driven hACE2-transgenic mice. JCI Insight 2021 10;6(19)
Asaka MN et al
2021/01/01
PubMed
13 Tsuji K et al. Development of alveolar and airway cells from human iPS cells: toward SARS-CoV-2 research and drug toxicity testing. J Toxicol Sci 2021;46(9):425-435
Tsuji K et al
2021/01/01
PubMed
14 Meng B et al. Altered TMPRSS2 usage by SARS-CoV-2 Omicron impacts tropism and fusogenicity. Nature 2022 Feb;
Meng B et al
2022/01/01
PubMed
15 Suzuki R et al. Attenuated fusogenicity and pathogenicity of SARS-CoV-2 Omicron variant. Nature 2022 Feb;
Suzuki R et al
2022/01/01
PubMed
16 Wright T et al. Photodynamic and Contact Killing Polymeric Fabric Coating for Bacteria and SARS-CoV-2. ACS Appl Mater Interfaces 2022 Jan;14(1):49-56
Wright T et al
2022/01/01
PubMed
17 Jiang W et al. A two-adjuvant multiantigen candidate vaccine induces superior protective immune responses against SARS-CoV-2 challenge. Cell Rep 2021 12;37(11):110112
Jiang W et al
2021/01/01
PubMed
18 Conforti A et al. COVID-eVax, an electroporated DNA vaccine candidate encoding the SARS-CoV-2 RBD, elicits protective responses in animal models. Mol Ther 2022 01;30(1):311-326
Conforti A et al
2022/01/01
PubMed
19 Ohno M et al. Abnormal Blood Coagulation and Kidney Damage in Aged Hamsters Infected with Severe Acute Respiratory Syndrome Coronavirus 2. Viruses 2021 10;13(11)
Ohno M et al
2021/01/01
PubMed
20 Sacco MD et al. Structure and inhibition of the SARS-CoV-2 main protease reveal strategy for developing dual inhibitors against M<sup>pro</sup> and cathepsin L. Sci Adv 2020 12;6(50)
Sacco MD et al
2020/01/01
PubMed
21 Yasui F et al. Infection with the SARS-CoV-2 B.1.351 variant is lethal in aged BALB/c mice. Sci Rep 2022 Mar;12(1):4150
Yasui F et al
2022/01/01
PubMed
22 Seifert M et al. Inhibition of SARS-CoV-2 polymerase by nucleotide analogs from a single-molecule perspective. Elife 2021 Oct;10
Seifert M et al
2021/01/01
PubMed
23 Ma C et al. Discovery of SARS-CoV-2 Papain-like Protease Inhibitors through a Combination of High-Throughput Screening and a FlipGFP-Based Reporter Assay. ACS Cent Sci 2021 Jul;7(7):1245-1260
Ma C et al
2021/01/01
PubMed
24 Argueta LB et al. SARS-CoV-2 Infects Syncytiotrophoblast and Activates Inflammatory Responses in the Placenta. bioRxiv 2021 Jun;
Argueta LB et al
2021/01/01
PubMed
25 Ma H et al. Potent Neutralization of SARS-CoV-2 by Hetero-bivalent Alpaca Nanobodies Targeting the Spike Receptor-Binding Domain. J Virol 2021 Mar;95(10)
Ma H et al
2021/01/01
PubMed
26 Gupta R. SARS-CoV-2 Omicron spike mediated immune escape and tropism shift. Res Sq 2022 Jan;
Gupta R
2022/01/01
PubMed
27 Kitamura N et al. Expedited Approach toward the Rational Design of Noncovalent SARS-CoV-2 Main Protease Inhibitors. J Med Chem 2022 Feb;65(4):2848-2865
Kitamura N et al
2022/01/01
PubMed
28 Argueta LB et al. Inflammatory responses in the placenta upon SARS-CoV-2 infection late in pregnancy. iScience 2022 May;25(5):104223
Argueta LB et al
2022/01/01
PubMed
29 Shapira T et al. A&#xFEFF; TMPRSS2 inhibitor acts as a pan-SARS-CoV-2 prophylactic and therapeutic. Nature 2022 May;605(7909):340-348
Shapira T et al
2022/01/01
PubMed
  • No.: 1
  • 文献情報:
    Shapira T. et al., Shapira T., bioRxiv, 2021

  • 備考:
  • 参照:
    PubMed
  • No.: 2
  • 文献情報:
    Ruetalo N et al. Antibody Response against SARS-CoV-2 and Seasonal Coronaviruses in Nonhospitalized COVID-19 Patients. mSphere 2021 02;6(1)
    Ruetalo N et al
    2021/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 3
  • 文献情報:
    Song E et al. Neuroinvasion of SARS-CoV-2 in human and mouse brain. J Exp Med 2021 03;218(3)
    Song E et al
    2021/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 4
  • 文献情報:
    Heaton BE et al. SRSF protein kinases 1 and 2 are essential host factors for human coronaviruses including SARS-CoV-2. bioRxiv 2020 Aug;
    Heaton BE et al
    2020/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 5
  • 文献情報:
    Ramani A et al. SARS-CoV-2 targets neurons of 3D human brain organoids. EMBO J 2020 10;39(20):e106230
    Ramani A et al
    2020/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 6
  • 文献情報:
    Eric Song et al., Eric Song, bioRxiv, 2020

  • 備考:
  • 参照:
    PubMed
  • No.: 7
  • 文献情報:
    Song E et al. Neuroinvasion of SARS-CoV-2 in human and mouse brain. bioRxiv 2020 Sep;
    Song E et al
    2020/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 8
  • 文献情報:
    Sasaki M et al. SARS-CoV-2 Bearing a Mutation at the S1/S2 Cleavage Site Exhibits Attenuated Virulence and Confers Protective Immunity. mBio 2021 08;12(4):e0141521
    Sasaki M et al
    2021/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 9
  • 文献情報:
    Sacco MD et al. Structure and inhibition of the SARS-CoV-2 main protease reveals strategy for developing dual inhibitors against M<sup>pro</sup> and cathepsin L. bioRxiv 2020 Jul;
    Sacco MD et al
    2020/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 10
  • 文献情報:
    . Pharmacological activation of STING blocks SARS-CoV-2 infection. Sci Immunol 2021 05;6(59)

    2021/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 11
  • 文献情報:
    Garc鱈a-Dorival I et al. Identification of Niemann-Pick C1 protein as a potential novel SARS-CoV-2 intracellular target. Antiviral Res 2021 10;194:105167
    Garc鱈a-Dorival I et al
    2021/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 12
  • 文献情報:
    Asaka MN et al. Highly susceptible SARS-CoV-2 model in CAG promoter-driven hACE2-transgenic mice. JCI Insight 2021 10;6(19)
    Asaka MN et al
    2021/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 13
  • 文献情報:
    Tsuji K et al. Development of alveolar and airway cells from human iPS cells: toward SARS-CoV-2 research and drug toxicity testing. J Toxicol Sci 2021;46(9):425-435
    Tsuji K et al
    2021/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 14
  • 文献情報:
    Meng B et al. Altered TMPRSS2 usage by SARS-CoV-2 Omicron impacts tropism and fusogenicity. Nature 2022 Feb;
    Meng B et al
    2022/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 15
  • 文献情報:
    Suzuki R et al. Attenuated fusogenicity and pathogenicity of SARS-CoV-2 Omicron variant. Nature 2022 Feb;
    Suzuki R et al
    2022/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 16
  • 文献情報:
    Wright T et al. Photodynamic and Contact Killing Polymeric Fabric Coating for Bacteria and SARS-CoV-2. ACS Appl Mater Interfaces 2022 Jan;14(1):49-56
    Wright T et al
    2022/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 17
  • 文献情報:
    Jiang W et al. A two-adjuvant multiantigen candidate vaccine induces superior protective immune responses against SARS-CoV-2 challenge. Cell Rep 2021 12;37(11):110112
    Jiang W et al
    2021/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 18
  • 文献情報:
    Conforti A et al. COVID-eVax, an electroporated DNA vaccine candidate encoding the SARS-CoV-2 RBD, elicits protective responses in animal models. Mol Ther 2022 01;30(1):311-326
    Conforti A et al
    2022/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 19
  • 文献情報:
    Ohno M et al. Abnormal Blood Coagulation and Kidney Damage in Aged Hamsters Infected with Severe Acute Respiratory Syndrome Coronavirus 2. Viruses 2021 10;13(11)
    Ohno M et al
    2021/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 20
  • 文献情報:
    Sacco MD et al. Structure and inhibition of the SARS-CoV-2 main protease reveal strategy for developing dual inhibitors against M<sup>pro</sup> and cathepsin L. Sci Adv 2020 12;6(50)
    Sacco MD et al
    2020/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 21
  • 文献情報:
    Yasui F et al. Infection with the SARS-CoV-2 B.1.351 variant is lethal in aged BALB/c mice. Sci Rep 2022 Mar;12(1):4150
    Yasui F et al
    2022/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 22
  • 文献情報:
    Seifert M et al. Inhibition of SARS-CoV-2 polymerase by nucleotide analogs from a single-molecule perspective. Elife 2021 Oct;10
    Seifert M et al
    2021/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 23
  • 文献情報:
    Ma C et al. Discovery of SARS-CoV-2 Papain-like Protease Inhibitors through a Combination of High-Throughput Screening and a FlipGFP-Based Reporter Assay. ACS Cent Sci 2021 Jul;7(7):1245-1260
    Ma C et al
    2021/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 24
  • 文献情報:
    Argueta LB et al. SARS-CoV-2 Infects Syncytiotrophoblast and Activates Inflammatory Responses in the Placenta. bioRxiv 2021 Jun;
    Argueta LB et al
    2021/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 25
  • 文献情報:
    Ma H et al. Potent Neutralization of SARS-CoV-2 by Hetero-bivalent Alpaca Nanobodies Targeting the Spike Receptor-Binding Domain. J Virol 2021 Mar;95(10)
    Ma H et al
    2021/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 26
  • 文献情報:
    Gupta R. SARS-CoV-2 Omicron spike mediated immune escape and tropism shift. Res Sq 2022 Jan;
    Gupta R
    2022/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 27
  • 文献情報:
    Kitamura N et al. Expedited Approach toward the Rational Design of Noncovalent SARS-CoV-2 Main Protease Inhibitors. J Med Chem 2022 Feb;65(4):2848-2865
    Kitamura N et al
    2022/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 28
  • 文献情報:
    Argueta LB et al. Inflammatory responses in the placenta upon SARS-CoV-2 infection late in pregnancy. iScience 2022 May;25(5):104223
    Argueta LB et al
    2022/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 29
  • 文献情報:
    Shapira T et al. A&#xFEFF; TMPRSS2 inhibitor acts as a pan-SARS-CoV-2 prophylactic and therapeutic. Nature 2022 May;605(7909):340-348
    Shapira T et al
    2022/01/01
  • 備考:
  • 参照:
    PubMed